StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Beam Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -242.3%. For fiscal 2025 it was -274.6%, against -654.3% the year before. The highest annual figure on record is -46.7% in fiscal 2023.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-274.6%+379.7
FY2024Dec 31, 2024-654.3%−607.5
FY2023Dec 31, 2023-46.7%+508.9
FY2022Dec 31, 2022-555.6%+201.4
FY2021Dec 31, 2021-757.0%+552409.7
FY2020Dec 31, 2020-553166.7%−135644.4
FY2019Dec 31, 2019-417522.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-25827.1%−24407.9
Q1 FY2026Mar 31, 2026-337.8%+1259.1
Q4 FY2025Dec 31, 2025-15.3%+317.4
Q3 FY2025Sep 30, 2025-1307.6%−561.2
Q2 FY2025Jun 30, 2025-1419.2%−528.2
Q1 FY2025Mar 31, 2025-1596.9%−191.6
Q4 FY2024Dec 31, 2024-332.7%−374.7
Q3 FY2024Sep 30, 2024-746.4%−116.7
Q2 FY2024Jun 30, 2024-891.1%−383.3
Q1 FY2024Mar 31, 2024-1405.3%−996.6
Q4 FY2023Dec 31, 202342.0%+486.1
Q3 FY2023Sep 30, 2023-629.7%−51.8
Q2 FY2023Jun 30, 2023-507.8%−15.6
Q1 FY2023Mar 31, 2023-408.7%+495.3
Q4 FY2022Dec 31, 2022-444.1%−319.8
Q3 FY2022Sep 30, 2022-577.9%+8548.4
Q2 FY2022Jun 30, 2022-492.2%+982407.8
Q1 FY2022Mar 31, 2022-904.0%+3338646.0
Q4 FY2021Dec 31, 2021-124.3%+679859.0
Q3 FY2021Sep 30, 2021-9126.3%+612890.3
Q2 FY2021Jun 30, 2021-982900.0%−544816.7
Q1 FY2021Mar 31, 2021-3339550.0%−2866966.7
Q4 FY2020Dec 31, 2020-679983.3%−240466.7
Q3 FY2020Sep 30, 2020-622016.7%−321616.7
Q2 FY2020Jun 30, 2020-438083.3%−143900.0
Q1 FY2020Mar 31, 2020-472583.3%–
Q4 FY2019Dec 31, 2019-439516.7%–
Q3 FY2019Sep 30, 2019-300400.0%–
Q2 FY2019Jun 30, 2019-294183.3%–

More Beam Therapeutics figures

See a number that looks wrong?